Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Clinical Trial

Official title: Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers

Status Completed

Clinical Trial Summary

The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Coronavirus Infections
• Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
• Syndrome

• NCT number: NCT04588428
• Study type: Interventional
• Source: Inovio Pharmaceuticals
• Status: Completed
• Phase: Phase 2
• Start date: June 21, 2021
• Completion date: January 19, 2023